nplate privacy optin

In the TOP-1 trial, omitting RT and endocrine therapy after breast-conserving surgery yielded a 14.8% 5-year local recurrence risk in women aged 70 and older.

A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

Data from the phase 3 HARMONi-GI1 trial support first-line ivonescimab plus chemotherapy as a new standard of care in advanced biliary tract cancer.

Based on data from the phase 3 SAFFRON trial, osimertinib plus savolitinib may establish a new global standard of care in this EGFR-mutated NSCLC population.

Sone-Ve significantly improved OS vs investigator’s choice in previously treated CLDN18.2-positive gastroesophageal carcinoma in CLARITY-Gastric01.

Data from the phase 3 Krascendo 1 trial support divarasib as a new standard in previously treated KRAS G12C–mutated non–small cell lung cancer.

Triplets did not beat pembrolizumab plus lenvatinib in frontline RCC, while belzutifan plus lenvatinib and perioperative pembrolizumab showed benefit.

Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.